Selective inhibition of Janus kinase 1 with upadacitinib shows promise in the treatment of rheumatoid arthritis patients with inadequate response to biologic or conventional synthetic disease-modifying antirheumatic drugs, according to data from two phase III trials.
The use of the investigational selective Janus kinase 1 (JAK1) inhibitor upadacitinib, either alone or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), led to rapid and significant clinical improvements in patients with moderate-to-severe rheumatoid arthritis (RA), including those who had been refractory to biologic DMARDs (bDMARDs), according to two multicentre phase III trials.
Patients with active rheumatoid arthritis (RA) who had inadequate response or intolerance to methotrexate had better patient-reported outcomes (PROs) with the anti-interleukin (IL)-6 receptor monoclonal antibody sarilumab compared with the widely used biologic disease-modifying antirheumatic drug (bDMARD) adalimumab, translating to an improved general health status, physical function, and participation, the MONARCH* study showed.
Though the VIGOR* trial ended many years ago, the outcomes its accompanying events continued to affect clinical practice, even when newer trials, such as PRECISION**, emerged to debunk much of the misconceptions generated by VIGOR.
Patients with rheumatoid arthritis (RA) who have received the monoclonal antibody adalimumab with serum trough concentrations above 8 μg/mL may safely prolong their dosing interval to once every 3 weeks without loss of disease control, according to a Dutch study.
Patients with systemic lupus erythematosus on hydroxychloroquine fare better, having lower mortality rates compared with those not using the drug, a study has shown. This survival benefit is further enhanced by treatment adherence.
Dr Sue-Ann Ng, Associate Consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, speaks to Roshini Claire Anthony on the multisystemic autoimmune disease that is systemic sclerosis (SSc) and the importance of early identification of the condition.
The human anti-interleukin (IL)-1β monoclonal antibody canakinumab continued to show optimal control of disease activity (ie, one or no new flare, no uptitration) in patients with colchicine-resistant familial Mediterranean fever (crFMF), TNF* receptor-associated periodic syndrome (TRAPS), and hyper IgD** syndrome (HIDS)/mevalonate kinase deficiency (MKD) after 112 weeks, according to results from the fourth phase of the CLUSTER*** trial presented at EULAR 2018.
The use of the bisphosphonate risedronate led to a significant reduction in periprosthetic bone mineral density (BMD) loss around an uncemented femoral stem for up to 6 months following total hip arthroplasty (THA), a meta-analysis has shown.
Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.
Although many patients with atopic dermatitis (AD) use antihistamines, no high-level evidence exists to prove that nonsedating antihistamines reduce itch in patients with AD or provide benefit in controlling AD symptoms, except perhaps sleep and AD comorbidities such as allergic rhinitis, according to a study.